Viatris to buy two eye drug developers in deals worth up to $750M

Pharmaceutical company Viatris will acquire the eye disease drug developers Oyster Point Pharma and Famy Life Sciences in separate deals announced Monday. Together, the acquisitions will cost Viatris between $700 million and $750 million, which the generics drugmaker plans to pay with cash it has on hand.